FealtySign in

LABCORP HOLDINGS INC.

(LH)

CIK 920148 · SEC filings only

Not yet gradedBuyback record
harness minimum not met
company entity
1 resolved promise

Not enough resolved promises to grade

1 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (3)

Open · buyback authorization

the authorization of a $2.5 billion share repurchase program

unresolved — no outcome on file$2.5000receipt →
Open · buyback authorization

the Board of Directors has approved an additional $1.00 billion for share repurchases

unresolved — no outcome on file$1.0000receipt →
Open · buyback authorization

Board of Directors approved an increase in share repurchase authorization by $1.0 billion to a total of $1.4 billion

next filing due$1.4000receipt →

Credibility timeline

PARTIAL · Oct 31, 2025
20252025
Timeline as a list
  • Oct 31, 2025PARTIALAnnounced a $1.0 billion accelerated share repurchase program
1 resolved buyback promise · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
BGuidance record
grade
company entity
5 resolved promises

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (20)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Feb 17, 2026
    Adjusted EPS of $17.55 to $18.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Feb 6, 2025
    Adjusted EPS of $15.60 to $16.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Oct 24, 2024
    Adjusted EPS range of $14.30 to $14.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Aug 1, 2024
    Adjusted EPS range of $14.30 to $14.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Feb 15, 2024
    Adjusted EPS $13.56 $14.30 $15.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Oct 26, 2023
    Adjusted EPS $16.66 $13.00 $14.00 $13.25 $13.75
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Jul 27, 2023
    Adjusted EPS of $13.00 to $14.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Apr 25, 2023
    Adjusted EPS narrowed to $16.25 to $17.75
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Feb 16, 2023
    Adjusted EPS $19.94 $16.00 $18.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Oct 27, 2022
    Adjusted EPS $28.52 $19.00 $21.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Apr 28, 2022
    Adjusted EPS improved to $18.25 to $21.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Feb 10, 2022
    Adjusted EPS $28.52 $17.25 $21.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Oct 28, 2021
    Adjusted EPS raised to range of $26.00 to $28.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Jul 29, 2021
    Adjusted EPS raised to range of $21.50 to $25.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Apr 29, 2021
    Adjusted EPS raised to $20.00 to $24.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Feb 11, 2021
    Adjusted EPS $ 23.94  $ 19.00  $ 23.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Apr 29, 2020
    expects to deliver solid adjusted EPS
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Feb 13, 2020
    Adjusted EPS of $11.75 to $12.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Apr 30, 2019
    Adjusted EPS of $11.05 to $11.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · Oct 20, 2011
    Adjusted EPS Excluding Amortization of $6.28 to $6.33
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (3) · 12 superseded

Open · revenue guidance fy

expecting revenue growth of approximately 10.5% - 11.0%

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Total Labcorp Enterprise (1)(2) $16.1

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Revenue of $14.61 billion to $14.79 billion

resolves in ~198 daysreceipt →
Superseded · revenue guidance fy

Revenue Total Labcorp Enterprise (1)(2) $ 13.98  (1.0%) 4.5%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenue range of 6.4% to 7.5%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Total Labcorp Enterprise (1)(2) $16.1

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenue Total Labcorp Enterprise (1)(2) $16.1 (6.5%) (1.5%)

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenue raised to range of 6.5% to 9.0%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Total Labcorp Enterprise (1)(2) $11.9

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenue raised to 2.0% to 6.5%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenue Total Labcorp Enterprise (1)(2) $14.9

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenue Labcorp Enterprise (1)(2) $12.2

revised by a later guidance$12.2000receipt →
Superseded · revenue guidance fy

Total Labcorp Enterprise (1)(2) $16.1

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenue Labcorp Enterprise (1)(2) $12.2

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Total Labcorp Enterprise (1)(2) $14.9 1.0% 4.0% 1.5% 4.0%

revised by a later guidancereceipt →

Credibility timeline

KEPT · Feb 28, 2020WITHDRAWN · Apr 29, 2020WITHDRAWN · Apr 29, 2020MISSED · Feb 28, 2023KEPT · Feb 26, 2024KEPT · Feb 25, 2025KEPT · Feb 24, 2026
20202026
Timeline as a list
  • Feb 28, 2020KEPTRevenue growth of 0.5% to 2.5% over 2018 revenue of $11.33 billion
  • Apr 29, 2020WITHDRAWNLabCorp withdraws 2020 guidance
  • Apr 29, 2020WITHDRAWNRevenue growth of 4.0% to 6.0% over 2019 revenue of $11.55 billion
  • Feb 28, 2023MISSEDRevenue raised to range of 13.0% to 14.0%
  • Feb 26, 2024KEPTTotal Labcorp Enterprise (1)(2) $11.86 1.5% 3.0% 1.9% 2.7%
  • Feb 25, 2025KEPTRevenue range of 6.6% to 7.3%
  • Feb 24, 2026KEPTRevenue of $13.88 billion to $14.05 billion
5 resolved guidance promises · 20dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →